Purple Biotech (NASDAQ: PPBT) is an innovative clinical stage oncology-focused company. We provide cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance.

The Company's oncology pipeline includes CAPTN-3 platform (conditionally activated tri-specific antibodies, which engage both T cells and NK cells), CM24 (anti-CEACAM1 mAb, completed P2) and NT219 (small molecule, degrading IRS1/2 and blocking IGF1R/IRS1 and STAT3 P2 is ongoing).

**Purple Biotech does not accept invitations from service providers at the business partnering. We appreciate your understanding.**